Table 4.
Baseline characteristics of the patients according to the subcategorized groups of HT.
| Variables | non-HT (n = 182) | HI (n = 110) | PH (n = 72) | P-value |
|---|---|---|---|---|
| Patient characteristics | ||||
| Age (years) | 74.0 (66.0–80.0) | 73.0 (64.0–80.0) | 77.0 (67.0–81.0) | 0.195 |
| Male, n (%) | 101 (55.5%) | 62 (56.4%) | 42 (58.3%) | 0.919 |
| BMI (kg/m2) | 24.0 (22.2–26.9) | 22.4 (21.2–26.0) | 22.4 (20.1–26.3) | 0.031 |
| History of stroke, n (%) | 45 (24.7%) | 25 (22.7%) | 17 (23.6%) | 0.926 |
| History of atrial fibrillation, n (%) | 17 (9.3%) | 26 (23.6%) | 29 (40.3%) | <0.001 |
| History of hypertension, n (%) | 140 (76.9%) | 75 (68.2%) | 54 (75.0%) | 0.250 |
| History of diabetes, n (%) | 54 (29.7%) | 34 (30.9%) | 19 (26.4%) | 0.802 |
| History of dyslipidemia, n (%) | 4 (2.2%) | 6 (5.5%) | 1 (1.4%) | 0.260 |
| Smoking status, n (%) | 0.607 | |||
| Nonsmokers | 132 (72.5%) | 81 (73.6%) | 59 (81.9%) | |
| Former smokers | 17 (9.3%) | 9 (8.2%) | 5 (6.9%) | |
| Current smokers | 33 (18.1%) | 20 (18.2%) | 8 (11.1%) | |
| Current drinking, n (%) | 26 (14.3%) | 19 (17.3%) | 11 (15.3%) | 0.790 |
| Biochemistry and vital signs on admission | ||||
| Baseline SBP (mmHg) | 154.5 ± 21.2 | 152.5 ± 23.5 | 153.5 ± 22.5 | 0.803 |
| White cell count, 109/L | 7.0 (5.8–8.4) | 8.8 (6.8–11.0) | 9.3 (7.2–12.4) | <0.001 |
| Lymphocyte count, 109/L | 1.6 (1.2–2.0) | 1.3 (1.0–1.9) | 1.2 (0.8–1.6) | <0.001 |
| Albumin, (g/L) | 40.0 (37.4–41.9) | 37.7 (35.3–40.5) | 37.3 (33.9–40.4) | <0.001 |
| Fibrinogen (g/L) | 3.4 (2.9–3.8) | 3.5 (2.9–4.3) | 3.7 (2.9–4.4) | 0.053 |
| Total cholesterol (mmol/L) | 4.4 (3.7–5.0) | 4.2 (3.4–5.0) | 4.3 (3.6–4.9) | 0.499 |
| Large size of the infarction area, n (%) | 19 (10.4%) | 52 (47.3%) | 39 (54.2%) | <0.001 |
| NIHSS on admission, median (IQR) | 4.0 (2.0–8.0) | 8.0 (3.0–14.0) | 15.0 (10.0–24.0) | <0.001 |
| Thrombolytic therapy, n (%) | 26 (14.3%) | 25 (22.7%) | 14 (19.4%) | 0.175 |
| Anticoagulants therapy before admission, n (%) | 4 (2.2%) | 9 (8.2%) | 6 (8.3%) | 0.021 |
| Antiplatelets therapy before admission, n (%) | 12 (6.6%) | 5 (4.5%) | 5 (6.9%) | 0.739 |
| CONUT, median (IQR) | 2.0 (1.0–3.0) | 2.0 (1.0–4.0) | 3.0 (2.0–4.0) | <0.001 |
| Malnutrition | <0.001 | |||
| Normal, n (%) | 88 (49.4%) | 32 (30.8%) | 15 (23.8%) | |
| Mild, n (%) | 78 (43.8%) | 56 (53.8%) | 33 (52.4%) | |
| Moderate-severe, n (%) | 12 (6.7%) | 16 (15.4%) | 15 (23.8%) | |
| Stroke mechanisms | <0.001 | |||
| Atherosclerotic, n (%) | 134 (73.6%) | 50 (45.5%) | 25 (34.7%) | |
| Cardioembolic, n (%) | 27 (14.8%) | 55 (50.0%) | 46 (63.9%) | |
| Lacunar, n (%) | 21 (11.5%) | 0 (0.0%) | 0 (0.0%) | |
| Other causes, n (%) | 0 (0.0%) | 5 (4.5%) | 1 (1.4%) | |
AIS, acute ischemic stroke; HT, hemorrhagic transformation; HI, hemorrhagic infarct; PH, parenchymal hematoma; BMI, body mass index; SBP, systolic blood pressure; NIHSS, National Institutes of Health Stroke Scale; and CONUT, controlling nutritional status score. The bold values indicate the P values to highlight the analysis results.